WO1998038183A1 - Kreatin-ascorbate und verfahren zu deren herstellung - Google Patents
Kreatin-ascorbate und verfahren zu deren herstellung Download PDFInfo
- Publication number
- WO1998038183A1 WO1998038183A1 PCT/EP1998/001104 EP9801104W WO9838183A1 WO 1998038183 A1 WO1998038183 A1 WO 1998038183A1 EP 9801104 W EP9801104 W EP 9801104W WO 9838183 A1 WO9838183 A1 WO 9838183A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- creatine
- ascorbates
- ascorbic acid
- ascorbate
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
Definitions
- the present application relates to creatine ascorbates and their preparation, which are anhydrous or water-containing salts of ascorbic acid with creatine and mixtures of these salts with creatine or ascorbic acid.
- Ascorbic acid (L- (-t-) ascorbic acid, vitamin C, L-3-keto-threo-2-hexuronic acid hactone, (R) -5 - [(S) -1, 2-dihydroxy-ethyl] -3 , 4-dihydroxy-5H-furan-2-one) is an essential nutritional component for maintaining human health. It is known that ascorbic acid or its salts (ascorbates) have valuable physiological, prophylactic and therapeutic properties for the treatment of various diseases. Since the discovery of the most serious vitamin C deficiency disease, scurvy and its healing by ascorbic acid, many interesting effects of this compound have been described.
- ascorbic acid The most important property of ascorbic acid is the reversible oxidation to dehydro-L-ascorbic acid, which is of crucial importance for the physiological effect as an antioxidant. Together with other antioxidants such as carotenes, glutathione and vitamin E, ascorbic acid acts as a scavenger for free radicals and oxidizing oxygen species. Furthermore, ascorbic acid can regenerate vitamin E. The antioxidant effect of ascorbic acid activates the immune system and reduces the risk of cancer. Ascorbic acid has a positive effect on cholesterol metabolism, which leads to a reduction in vascular and especially cardiovascular diseases. Also important are the functions of ascorbic acid as an enzyme stimulant or cofactor of oxygenases, which among other things cause the synthesis of dopamine and carnitine. Vitamin C is also recommended in the treatment of anemia because it promotes iron absorption from food (see Ullmann's Encyclopedia of Industrial Chemistry, 5 th ed., 1 996 vol. A27, p. 547-559).
- Creatine is found in muscle and nerve tissue (especially in the CNS) and, in the form of its metabolic secondary product, phosphocreatine, represents an energy reserve for the muscle and brain.
- creatine appears to have a prophylactic and therapeutic effect in ischemia, such as you eg due to infarction or pre- and perinatal oxygen deficit states.
- Creatine is not only an endogenous substance and a valuable nutritional supplement, but also has valuable therapeutic properties. Creatine has been known as a muscle substance for over a hundred years, using the muscle as a source of energy. A number of scientific studies have shown that taking creatine can lead to an increase in muscle mass and muscle performance.
- pancreas releases more insulin under the influence of creatine. Insulin promotes the absorption of glucose and amino acids in the muscle cell and stimulates protein synthesis. Insulin also reduces the rate of protein breakdown.
- the prophylactic, therapeutic or dietary use of creatine in a wide variety of application forms requires high bioavailability and therefore good water solubility. This is not sufficient for creatine, which is an amino acid derivative in the form of an inner salt.
- the object of the present invention was therefore to develop forms of creatine which are particularly valuable physiologically and at the same time have good water solubility and adequate storage stability.
- z 1 to 100, preferably 1 to 5
- y 1 to 100, preferably 1 to 5
- n 0 to 20, preferably 0 to 2.
- creatine can be present in the compounds of the formula (I) in an uncharged form or as a cation and ascorbate as ascorbic acid or as an anion.
- the creatine ascorbates according to the invention have good storage stability, although the known salts of creatine decompose to form creatinine. Since creatine is present as an inner salt and is only a weak base, it could not be expected that stable creatine salts can be produced with acidic enols. According to the state of the art, only creatine salts of strong di- and tricarboxylic acids have so far been known (cf. WO 96/04 240), but strongly acidic hydrogen salts are formed.
- the creatine ascorbates of the general formula (I) according to the invention contain the physiologically particularly valuable creatine cation of the formula (II) and the ascorbate anion of the formula (III)
- the creatine ascorbates according to the invention comprise salts which contain the creatine cation and the ascorbate anion preferably in a molar ratio of 1: 1 or approximately in a molar ratio of 1: 1.
- the creatine ascorbates according to the invention can also be mixtures of these salts with creatine or ascorbic acid.
- the creatine ascorbates according to the invention can be prepared by relatively simple reaction of creatine with ascorbic acid in the temperature range from -10 to 90 ° C., preferably in the temperature range from 10 to 30 ° C.
- creatine and ascorbic acid are reacted in a molar ratio of 100: 1 to 1: 100 and preferably 5: 1 to 1: 5.
- Creatine can be used in anhydrous form as a monohydrate or as a moist product.
- the ascorbic acid can be used as an anhydrous acid or in the form of an aqueous solution.
- the reaction can be carried out in the absence or in the presence of a solvent or diluent, a wide range of organic solvents being suitable as the solvent or diluent.
- Alcohols such as methanol, ethanol, isopropanol, Cyclohexanol
- ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, ethylenedimethyl ether
- ketones such as acetone, methyl ethyl ketone, cyclohexanone
- esters such as methyl acetate, ethyl acetate, ethyl formate
- the reaction can be carried out in the known process engineering apparatus such as in mixers, paddle dryers and stirred tanks.
- the water of crystalline creatine ascorbates can be obtained by adding water during or after the reaction of ascorbic acid with creatine or / and by using aqueous creatine and / or aqueous ascorbic acid.
- other substances such as pharmaceutical formulation auxiliaries, vitamins, minerals, trace elements, carbohydrates such as glucose, dextrose, maltose or amino acids such as L-carnitine or other nutritional supplements during or after production.
- the invention thus also relates to physiologically compatible compositions which contain creatine ascorbates together with at least one further physiologically compatible substance selected from the group comprising pharmaceutical auxiliaries or carriers, vitamins, minerals, colohydrates, ami nosä u ren or other food supplements.
- the creatine ascorbates according to the invention are outstandingly suitable for therapeutic applications in medicine and as food supplement additives, these not only having the known valuable biological and medical properties of ascorbates and of Possess creatine, but also surprisingly have clear synergistic effects.
- the creatine ascorbates according to the invention are particularly suitable for increasing muscle build-up and strength in the sports sector, for the prophylaxis and treatment of oxygen deficit conditions (ischemia) and immune stimulation in the health sector, for the treatment of muscular disorders and as a food supplement.
- ischemia oxygen deficit conditions
- immune stimulation in the health sector, for the treatment of muscular disorders and as a food supplement.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP98912408A EP0971911A1 (de) | 1997-02-26 | 1998-02-26 | Kreatin-ascorbate und verfahren zu deren herstellung |
AU67260/98A AU6726098A (en) | 1997-02-26 | 1998-02-26 | Creatine-ascorbates, production process |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19707694.7 | 1997-02-26 | ||
DE19707694A DE19707694A1 (de) | 1997-02-26 | 1997-02-26 | Kreatin-ascorbate und Verfahren zu deren Herstellung |
US08/898,512 US5863939A (en) | 1997-02-26 | 1997-07-22 | Creatine ascorbates and a method of producing them |
US08/898,512 | 1997-07-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998038183A1 true WO1998038183A1 (de) | 1998-09-03 |
Family
ID=26034305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1998/001104 WO1998038183A1 (de) | 1997-02-26 | 1998-02-26 | Kreatin-ascorbate und verfahren zu deren herstellung |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0971911A1 (de) |
AU (1) | AU6726098A (de) |
WO (1) | WO1998038183A1 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1002532A1 (de) * | 1998-11-19 | 2000-05-24 | K.U. Leuven Research & Development | Vorbeugung von Alterungserscheinungen und Behandlung der Muskelatrophie |
WO2001054676A2 (de) * | 2000-01-28 | 2001-08-02 | Degussa Ag | Formulierungen bei dehydratationszuständen |
EP2023718A2 (de) * | 2006-05-11 | 2009-02-18 | Avicena Group, Inc. | Kreatinligandverbindungen und anwendungsverfahren dafür |
US8613959B2 (en) | 2009-02-10 | 2013-12-24 | Fhg Corporation | Dietary supplements containing extracts of Nelumbo and processes of using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004240A1 (en) * | 1994-08-04 | 1996-02-15 | Flamma S.P.A. | Hydrosoluble organic salts of creatine |
GB2313544A (en) * | 1996-05-31 | 1997-12-03 | Howard Foundation | Improvements in or relating to compositions containing creatine |
-
1998
- 1998-02-26 WO PCT/EP1998/001104 patent/WO1998038183A1/de not_active Application Discontinuation
- 1998-02-26 EP EP98912408A patent/EP0971911A1/de not_active Withdrawn
- 1998-02-26 AU AU67260/98A patent/AU6726098A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996004240A1 (en) * | 1994-08-04 | 1996-02-15 | Flamma S.P.A. | Hydrosoluble organic salts of creatine |
GB2313544A (en) * | 1996-05-31 | 1997-12-03 | Howard Foundation | Improvements in or relating to compositions containing creatine |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1002532A1 (de) * | 1998-11-19 | 2000-05-24 | K.U. Leuven Research & Development | Vorbeugung von Alterungserscheinungen und Behandlung der Muskelatrophie |
WO2000030634A1 (en) * | 1998-11-19 | 2000-06-02 | K.U. Leuven Research & Development | Oral creatine supplementation for treating or preventing muscle disuse syndrome |
WO2001054676A2 (de) * | 2000-01-28 | 2001-08-02 | Degussa Ag | Formulierungen bei dehydratationszuständen |
WO2001054676A3 (de) * | 2000-01-28 | 2002-05-16 | Sueddeutsche Kalkstickstoff | Formulierungen bei dehydratationszuständen |
EP2023718A2 (de) * | 2006-05-11 | 2009-02-18 | Avicena Group, Inc. | Kreatinligandverbindungen und anwendungsverfahren dafür |
EP2023718A4 (de) * | 2006-05-11 | 2010-04-21 | Avicena Group Inc | Kreatinligandverbindungen und anwendungsverfahren dafür |
US8613959B2 (en) | 2009-02-10 | 2013-12-24 | Fhg Corporation | Dietary supplements containing extracts of Nelumbo and processes of using same |
Also Published As
Publication number | Publication date |
---|---|
EP0971911A1 (de) | 2000-01-19 |
AU6726098A (en) | 1998-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0894083B1 (de) | Kreatin-pyruvate und verfahren zu deren herstellung | |
DE19707694A1 (de) | Kreatin-ascorbate und Verfahren zu deren Herstellung | |
DE19653225A1 (de) | Kreatin-pyruvate und Verfahren zu deren Herstellung | |
DE2524355C2 (de) | Tetrahydropyranderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
DE19929993C2 (de) | Kreatin-alpha-ketoglutarate, Verfahren zu ihrer Herstellung und ihre Verwendung | |
DE2829580C2 (de) | 2-Formylchinoxalin-1,4-dioxid-cyanoacetylhydrazon, Verfahren zu seiner Herstellung und Zusammensetzungen mit dieser Verbindung | |
DE10065478C1 (de) | Kreatin/Citronensäure-Verbindung, Verfahren zu ihrer Herstellung und Verwendung | |
DE60200476T2 (de) | Kreatin-salz mit nahrungs- und therapeutischer verwendung und dieses enthaltende zusammensetzungen | |
EP0971911A1 (de) | Kreatin-ascorbate und verfahren zu deren herstellung | |
EP0190676B1 (de) | All-cis-1,3,5-Triamino2,4,6-cyclohexantriol-Derivate, ihre Verwendung, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Präparate | |
DE2725246C2 (de) | ||
DE3730277C2 (de) | Salz einer Organogermaniumverbindung und dessen Verwendung | |
EP1450629A1 (de) | Feste und stabile kreatin/citronensäure-zusammensetzung(en) und kohlenhydrate(e) bzw. deren hydrate enthaltende formulierung, verfahren zu ihrer herstellung und deren verwendung | |
DE1493618A1 (de) | Cumarinderivate und ein Verfahren zu ihrer Herstellung | |
AT392474B (de) | Verfahren zur herstellung von glucosylmoranolin | |
DE60008392T2 (de) | Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten | |
DE2536170C3 (de) | Flavonderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
EP0993433B1 (de) | Verfahren zur herstellung von calciumpyruvaten | |
DE2743944C3 (de) | 5-Alkoxy-picolinsäuren, Verfahren zur Herstellung derselben und blutdrucksenkende Arzneimittel, welche diese enthalten | |
EP0183194B1 (de) | Menadioncholinbisulfit-Addukt und Verfahren zu dessen Herstellung | |
DE1947256C3 (de) | Orotsäurederivate mit verbesserter Wasserlöslichkeit und Verfahren zu ihrer Herstellung | |
DE1770889A1 (de) | Wasserloesliche Mischungen von Sulfonamid- und Tetracyclin-Saeuresalzen | |
DE2148986B2 (de) | Salze der Chondroitinschwefelsäure mit Carboxymethyl-trimethylammoniumhydroxid, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel | |
AT300810B (de) | Verfahren zur Herstellung neuer Pyridoxinderivate | |
DE948159C (de) | Verfahren zur Herstellung von bimolekularem Carnitinchlorid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998912408 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998912408 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 1998537319 Format of ref document f/p: F |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998912408 Country of ref document: EP |